Literature DB >> 16503970

The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines.

John P Alao1, Simon C Gamble, Alexandra V Stavropoulou, Karen M Pomeranz, Eric W-F Lam, R Charles Coombes, David M Vigushin.   

Abstract

BACKGROUND: The cyclin D1 proto-oncogene is an important regulator of G1 to S-phase transition and an important cofactor for several transcription factors in numerous cell types. Studies on neonatal cardiomyocytes and postmitotic neurons indicate that the activity of cyclin D1 may be regulated through its cytoplasmic sequestration. We have demonstrated previously, that TSA induces the ubiquitin-dependent degradation of cyclin D1 in MCF-7 breast cancer cells. Additional studies were initiated in order to further investigate the effect of TSA on cyclin D1 regulation using sub-cellular fractionation techniques.
RESULTS: Our studies revealed cyclin D1 to be localized predominantly within the cytoplasmic fraction of all cell lines tested. These observations were confirmed by confocal microscopy. GSK3beta was found to be localized within both the nucleus and cytoplasm throughout the cell cycle. Inhibition of GSK3beta or CRM1-dependent nuclear export resulted in only modest nuclear accumulation, suggesting that the cytoplasmic localization of cyclin D1 results from the inhibition of its nuclear import.
CONCLUSION: We have shown by several different experimental approaches, that cyclin D1 is in fact a predominantly cytoplasmic protein in mammalian cancer cell lines. Recent studies have shown that the cytoplasmic sequestration of cyclin D1 prevents apoptosis in neuronal cells. Our results suggest that cytoplasmic sequestration may additionally serve to regulate cyclin D1 activity in mammalian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503970      PMCID: PMC1388232          DOI: 10.1186/1476-4598-5-7

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  23 in total

1.  Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288.

Authors:  Yonglong Zou; Daina Z Ewton; Xiaobing Deng; Stephen E Mercer; Eileen Friedman
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

2.  Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis.

Authors:  Yang Guo; Ke Yang; Jyoti Harwalkar; Jeffrey M Nye; David R Mason; Michelle D Garrett; Masahiro Hitomi; Dennis W Stacey
Journal:  Oncogene       Date:  2005-04-14       Impact factor: 9.867

3.  Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element.

Authors:  M Sabbah; D Courilleau; J Mester; G Redeuilh
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer.

Authors:  A Russell; M A Thompson; J Hendley; L Trute; J Armes; D Germain
Journal:  Oncogene       Date:  1999-03-18       Impact factor: 9.867

5.  Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins.

Authors:  Z K Yu; J L Gervais; H Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

6.  Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.

Authors:  John Patrick Alao; Eric W-F Lam; Simak Ali; Laki Buluwela; Walter Bordogna; Peter Lockey; Rana Varshochi; Alexandra V Stavropoulou; R Charles Coombes; David M Vigushin
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

7.  Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286.

Authors:  D Germain; A Russell; A Thompson; J Hendley
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

8.  Evaluation of cyclin D1 expression and its subcellular distribution in mouse tissues.

Authors:  Maria De Falco; Valentina Fedele; Luca De Luca; Roberta Penta; Giuliano Cottone; Ivan Cavallotti; Vincenza Laforgia; Antonio De Luca
Journal:  J Anat       Date:  2004-11       Impact factor: 2.610

9.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.

Authors:  J A Diehl; M Cheng; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  1998-11-15       Impact factor: 11.361

10.  The activities of cyclin D1 that drive tumorigenesis.

Authors:  Mark E Ewen; Justin Lamb
Journal:  Trends Mol Med       Date:  2004-04       Impact factor: 11.951

View more
  30 in total

Review 1.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

2.  Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cells.

Authors:  F Basso; F Rocchetti; S Rodriguez; M Nesterova; F Cormier; C A Stratakis; B Ragazzon; J Bertherat; M Rizk-Rabin
Journal:  Horm Metab Res       Date:  2014-09-30       Impact factor: 2.936

Review 3.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

4.  Cyclin D1 localizes in the cytoplasm of keratinocytes during skin differentiation and regulates cell-matrix adhesion.

Authors:  Rita Fernández-Hernández; Marta Rafel; Noel P Fusté; Rafael S Aguayo; Josep M Casanova; Joaquim Egea; Francisco Ferrezuelo; Eloi Garí
Journal:  Cell Cycle       Date:  2013-07-08       Impact factor: 4.534

Review 5.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

6.  WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase.

Authors:  Jen-Tai Lin; Hao-Yi Li; Nan-Shan Chang; Cheng-Han Lin; Yu-Chia Chen; Pei-Jung Lu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways.

Authors:  Jairam Vanamala; Lavanya Reddivari; Sridhar Radhakrishnan; Chris Tarver
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

8.  Potential effects of CRM1 inhibition in mantle cell lymphoma.

Authors:  Ke-Jie Zhang; Michael Wang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

9.  Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice.

Authors:  Guangchun Jin; Vigneshwaran Ramanathan; Michael Quante; Gwang Ho Baik; Xiangdong Yang; Sophie S W Wang; Shuiping Tu; Shanisha A K Gordon; David Mark Pritchard; Andrea Varro; Arthur Shulkes; Timothy C Wang
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

10.  Characterization of growth suppressive functions of a splice variant of cyclin D2.

Authors:  Karim Wafa; Jessica MacLean; Feixiong Zhang; Kishore B S Pasumarthi
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.